Global Focal Segmental Glomerulosclerosis Market, By Type (Primary, Secondary), Treatment (Drug Therapy, Dialysis, Kidney Transplant, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2031.
Focal Segmental Glomerulosclerosis Market Analysis and Size
The focal segmental glomerulosclerosis market is expected to witness significant growth during the forecast period. The occurrence of focal segmental glomerulosclerosis is comparatively high when compared to other glomerular diseases. Presently, there are no FDA-approved therapies for focal segmental glomerulosclerosis. The therapeutic market size of focal segmental glomerulosclerosis in the U.S. mostly accounted for the off-label treatment options, such as non-immune therapy in combination with immunotherapy.
Data Bridge Market Research analyzes that the global focal segmental glomerulosclerosis market, which was USD 24.01 billion in 2023, would rocket up to 47.50 billion by 2031 and is expected to undergo a CAGR of 8.9% during the forecast period. “Hospitals" dominate the end-user segment of the market due to increasing awareness of proper treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Focal Segmental Glomerulosclerosis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Primary, Secondary), Treatment (Drug Therapy, Dialysis, Kidney Transplant, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare (U.K.), Wockhardt (India)
|
|
Market Opportunities
|
|
Market Definition
Focal segmental glomerulosclerosis is a type of renal disorder affecting the small filtering unit of kidneys called glomeruli which involves scarring of kidney. It is caused by numerous factors such as autoimmune disorders, genetic factors, and infection in other parts of the body and sclerotic diseases. It is one of the rare diseases that affects kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, sickle cell anemia, obstructive sleep apnea, birth, and viruses such as HIV.
Global Focal Segmental Glomerulosclerosis Market Dynamics
Drivers
- Increased Prevalence of Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a rare health condition affecting about 210,200 patients globally and around 14,000 to 16,000 new cases are diagnosed annually. The increasing numbers along the considerable opportunities are boosting the growth of the market.
- Higher Therapeutic Options
The latest therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Additionally, steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the main evolving companies having their potential drug candidates in the pipeline are Chemocentryx, Pharmaceuticals, Retrophin Inc., Reata, and Vertex Pharmaceuticals. This boosts the market growth.
Opportunities
- Growing Elderly Population
Life expectancy is increasing all over the globe, which has led to an upsurge in the elderly population. This trend positively impacts the industry by increasing the disease occurrence and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) results in the sound growth of the focal segmental glomerulosclerosis market during the forecast period. Thus, it creates more opportunities for the market growth.
- Increased Diagnostic Tests
Several advances in pathogenesis of focal segmental glomerular sclerosis (FSGS) resulted in the market for research in the focal segmental glomerular sclerosis (FSGS). Several etiologies drive focal segmental glomerulosclerosis (FSGS). Rising awareness about occurrence of kidney disease drive prospects in the FSGS market. Given the increased mortality in patient populations, important advances were made in genetic testing, lab testing, and kidney biopsies. These new treatment methods are creating more opportunities for the market.
Restraints/Challenges
- Lack of Medical Care
The lack of medical care in undeveloped economies may restrain the growth of focal segmental glomerulosclerosis market during the forecast period. Not much awareness leads to the unavailability of treatment and limits market growth.
- High Cost
The huge expenditure associated with drug therapy, dialysis, kidney transplant hamper the market growth. The huge drug development and associated processes hamper the market's growth.
Global Focal Segmental Glomerulosclerosis Market Scope
The focal segmental glomerulosclerosis market is segmented on the basis of type, treatment, route of administration, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Primary
- Secondary
Treatment
- Drug Therapy
- Dialysis
- Kidney Transplant
- Others
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Focal Segmental Glomerulosclerosis Market Regional Analysis/Insights
The focal segmental glomerulosclerosis market is analyzed and market size insights and trends are provided by country type, treatment, route of administration, end-user, and distribution channel as referenced above.
The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East & Africa.
North America is expected to dominate the market due to the high diagnostic rate and presence of key players in this region.
Asia-Pacific is expected to show significant growth in the market throughout the forecasted period due to the growing cases of kidney disorder, the presence of sophisticated medical facilities to maximize the treatment effectiveness for a patient suffering from glomerular disease, and increased focus on research and development activity.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The focal segmental glomerulosclerosis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for focal segmental glomerulosclerosis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on focal segmental glomerulosclerosis market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Focal Segmental Glomerulosclerosis Market Share Analysis
The focal segmental glomerulosclerosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to focal segmental glomerulosclerosis market.
Some of the major players operating in the focal segmental glomerulosclerosis market are:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Accord Healthcare (U.K.)
- Wockhardt (India)
SKU-